Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Sep;10(Suppl 26):S3155-S3159.
doi: 10.21037/jtd.2018.07.92.

Atezolizumab in non-squamous non-small cell lung cancer

Takaki Akamine  1 , Gouji Toyokawa  1 , Tetsuzo Tagawa  1 , Takashi Seto  2
Affiliations
Editorial

Atezolizumab in non-squamous non-small cell lung cancer

Takaki Akamine et al. J Thorac Dis. 2018 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Takashi Seto reports grants from Bayer Yakuhin, Eisai, Merck Serono, Novartis Pharma, and Verastem; personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Mochida Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, Roche Singapore, Sanofi, Showa Yakuhin, Taiho Pharmaceutical and Takeda Pharmaceutical; grants and personal fees from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Pfizer Japan, YakultHonsha, outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Phase III IMpower trials for first-line treatment of non-Sq NSCLC. Bev, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; NSCLC, non-small cell lung cancer; PEM, pemetrexed; PTX, paclitaxel; R, randomized study; Sq, squamous.
Figure 2
Figure 2
Schematic diagram showing both the pathway for VEGF upregulation though EGFR/ALK gene alteration and its immunosuppressive role. ALK, anaplastic lymphoma kinase; DC, dendritic cell, EGFR, epidermal growth factor receptor; MDSC, myeloid-derived suppressor cells; T-reg, T-regulatory cells; VEGF, vascular endothelial growth factor.
See this image and copyright information in PMC

Comment on

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Clinical Trial.

References

    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed
    1. Pai-Scherf L, Blumenthal GM, Li H, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist 2017;22:1392-9. 10.1634/theoncologist.2017-0078 - DOI - PMC - PubMed
    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res 2015;3:1052-62. 10.1158/2326-6066.CIR-14-0191 - DOI - PubMed